1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Anhui Huaheng Biotechnology Co., Ltd. Class A

Anhui Huaheng Biotechnology Co., Ltd. Class A

SSSE:688639
17.34
CNY
+0.25
(+1.46%)
0.45EPS
31.06P/E
4.04BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.25
3.4
2.65
3.24
2.27
2.49
2.88
2.87
4.59
6.24
8.46
9.42
11.45
12.45
Basic EPS, GAAP
0.62
0.35
0.45
0.64
0.39
0.45
0.74
0.71
0.81
1.41
1.96
0.82
0.53
0.52
Free Cash Flow per Basic Share
0.89
0.17
-0.57
-0.04
0.34
0.15
0.59
0.22
-0.41
-0.43
-4.22
-3.13
-2.13
- -
Dividend per Share
0.3
0.3
0.37
0.08
0.19
0.03
0.44
0.02
0.18
0.26
0.48
0.79
0.44
0.37
Book Value per Share
0.21
0.56
1.19
1.83
2.18
3.21
2.16
2.16
5.21
6.5
8
10.27
10.58
10.82
Tangible Book Value per Share
0.06
0.42
0.95
1.47
1.85
2.89
1.91
1.97
5.02
6.17
7.62
9.72
9.98
10.23
Basic Weighted Avg Shares
21
66
96
96
168
169
170
170
208
227
229
231
250
249
Sales/Revenue/Turnover
173
225
253
311
383
421
491
487
954
1,419
1,938
2,178
2,862
3,103
Operating Margin (%)
10.11
10.13
18.7
22.38
21.73
21.03
30.43
29.26
19.41
23.29
26.56
10.25
6.58
6.59
Depreciation Expense
5
8
8
12
21
24
33
35
48
59
99
139
215
- -
Net Income, GAAP
13
23
43
62
65
76
126
121
168
320
449
190
132
129
Effective Tax Rate (%)
7.51
11.35
14.14
15.57
12.48
12.76
13.31
13.46
11.82
6.89
11.79
8.36
1.35
- -
Profit Margin (%)
7.5
10.22
16.89
19.84
16.96
17.94
25.72
24.85
17.63
22.56
23.17
8.7
4.63
4.17
Working Capital
-63
-30
18
8
3
37
54
100
670
474
-626
-252
125
325
LT Debt
- -
13
60
40
30
15
- -
- -
- -
- -
305
638
1,572
1,772
Total Equity
20
54
114
176
211
313
369
490
1,183
1,482
1,826
2,558
2,632
2,678
Return on Invested Capital (%)
14.15
18.95
22.39
21.81
21.38
20.8
29.78
23.05
18.61
22.84
19.27
5.07
2.9
- -
Return on Capital (%)
16.97
22.77
24.99
23.89
23.74
22.46
30.68
25.25
19.38
23.26
19.9
6.39
4.19
- -
Return on Common Equity (%)
92
61.66
50.78
42.51
33.54
28.84
37.08
28.21
20.11
24.03
27.15
8.63
5.08
4.86

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
486
642
730
LT Borrowings
1,572
1,725
1,772
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
250
250
250
Market Capitalization
8,149
7,093
4,037

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,464
1,732
1,807
Cash, Cash Equivalents & STI
284
446
550
Accounts Receivable, Net
271
265
281
Inventories
532
628
648
Total Current Liabilities
1,339
1,428
1,482
Payables & Accruals
- -
- -
- -
ST Debt
486
642
730
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.57%
46.6%
2.87%
Free Cash Flow
-102.3%
102.62%
-26.47%
Net Income, GAAP
21.05%
16.31%
-30.13%
Sales/Revenue/Turnover
29.65%
44.98%
31.4%
Total Cash Common Dividend
292.58%
276.95%
-39.58%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
501
515
523
639
2,178
2025
687
802
- -
668
2,862
2026
771
861
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.28
0.09
0.08
0.82
2025
0.2
0.26
- -
-0.14
0.53
2026
0.17
0.24
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.05
0.66
0.05
0.79
2025
0.04
0.05
- -
0.04
0.44
2026
0.06
0.23
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Heng Hua Guo
Full Time Employees
2,252
Sector
Health technology
Industry
Biotechnology
Address
No. 197, Chuangxin Avenue and Chang'an Road Hefei AN China 231031
IPO Date
Apr 22, 2021
Website
huahengbio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) engages in the research, development, production and sale of amino acids, vitamins, bio-based intermediates and monomers utilizing synthetic biotechnology. The company offers alanine series products including L-alanine, DL-alanine and beta-alanine; valine products such as L-valine; vitamin derivatives like D-pantothenate calcium and D-pantothenol; alpha-arbutin; malic acid; as well as branded solutions encompassing AH Synova bio-based material monomers, AHB pharmaceutical intermediates and bio-based chemicals, AH BIOSUS amino acids and peptides, VITAROSUS vitamins, AHB flavor agents, BIOPURENOL high-performance humectants and multifunctional solvents, BIOBLANCA whitening actives, BIOAGRI fertilizer enhancers and biostimulants; these serve intermediates, animal nutrition, personal care, plant nutrition, functional foods and human nutrition sectors. Founded on April 13, 2005 and headquartered at 32 Fengjin Road, Shuangfeng Industrial Zone, Hefei, Anhui Province, China, the company operates globally across more than 80 countries and regions, serving over 768 customers including Fortune 500 firms like BASF. In recent developments, Anhui Huaheng Biotechnology signed a strategic cooperation agreement with BASF Agricultural Solutions in May 2024 to jointly develop biostimulants and establish a Plant Nutrition Application R&D Institute for crop yield enhancement and resilience; achieved key breakthroughs in new products including 1,3-propanediol, succinic acid, tryptophan and arginine in 2024; and submitted an application in September 2025 for an H-share listing on the Hong Kong Stock Exchange, with Huatai International as sponsor, aiming to expand its dual-listing structure following its 2021 STAR Market debut.